Who are MVA-BN half-dose regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Smallpox and Mpox Vaccine, Measles, Mumps, and Rubella Virus Vaccine, JYNNEOS, M-M-RTM II, bOPV 1,3, measles-rubella vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mva-bn-half-dose-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MVA-BN half-dose regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MVA-BN half-dose regimen (MVA-BN half-dose regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated viral vaccine Monkeypox virus antigens (L1, A29, I3, I4, I5 proteins) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVA-BN half-dose regimen (MVA-BN half-dose regimen) — Jean-Pierre Van geertruyden. MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MVA-BN half-dose regimen TARGET	MVA-BN half-dose regimen	Jean-Pierre Van geertruyden	phase 3	Live attenuated viral vaccine	Monkeypox virus antigens (L1, A29, I3, I4, I5 proteins)
Smallpox and Mpox Vaccine	Smallpox and Mpox Vaccine	SIGA Technologies	marketed	Live attenuated viral vaccine / Recombinant viral vaccine
Measles, Mumps, and Rubella Virus Vaccine	Measles, Mumps, and Rubella Virus Vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated viral vaccine
JYNNEOS	JYNNEOS	Womack Army Medical Center	marketed	Live attenuated viral vaccine	Orthopoxvirus antigens (vaccinia virus envelope and core proteins)
M-M-RTM II	M-M-RTM II	Merck Sharp & Dohme LLC	marketed	Live attenuated viral vaccine
bOPV 1,3	bOPV 1,3	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Live attenuated viral vaccine	Poliovirus types 1 and 3
measles-rubella vaccine	measles-rubella vaccine	Sichuan Center for Disease Control and Prevention	marketed	Live attenuated viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated viral vaccine class)

Jean-Pierre Van geertruyden · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Centers for Disease Control and Prevention · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 1 drug in this class
Institute of Tropical Medicine, Belgium · 1 drug in this class
International Vaccine Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVA-BN half-dose regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/mva-bn-half-dose-regimen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab